Supernus Pharmaceuticals, Inc. (SUPN): Price and Financial Metrics

Supernus Pharmaceuticals, Inc. (SUPN): $33.34

1.42 (+4.45%)

POWR Rating

Component Grades














  • SUPN scores best on the Value dimension, with a Value rank ahead of 98.99% of US stocks.
  • SUPN's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
  • SUPN's current lowest rank is in the Sentiment metric (where it is better than 3.75% of US stocks).

SUPN Stock Summary

  • Supernus Pharmaceuticals Inc's stock had its IPO on May 1, 2012, making it an older stock than 32.99% of US equities in our set.
  • With a price/earnings ratio of 15.23, Supernus Pharmaceuticals Inc P/E ratio is greater than that of about 34.32% of stocks in our set with positive earnings.
  • As for revenue growth, note that SUPN's revenue has grown 38.31% over the past 12 months; that beats the revenue growth of 86.38% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Supernus Pharmaceuticals Inc, a group of peers worth examining would be MGRC, MTZ, GBL, FSS, and GMED.
  • Visit SUPN's SEC page to see the company's official filings. To visit the company's web site, go to

SUPN Price Target

For more insight on analysts targets of SUPN, see our SUPN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $35.00 Average Broker Recommendation 1.5 (Moderate Buy)

SUPN Stock Price Chart Interactive Chart >

Price chart for SUPN

SUPN Price/Volume Stats

Current price $33.34 52-week high $34.29
Prev. close $31.92 52-week low $17.20
Day low $32.00 Volume 555,985
Day high $34.29 Avg. volume 538,096
50-day MA $30.48 Dividend yield N/A
200-day MA $25.82 Market Cap 1.77B

Supernus Pharmaceuticals, Inc. (SUPN) Company Bio

Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The company was founded in 2005 and is based in Rockville, Maryland.

SUPN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$33.34$61.89 102%

Below please find a table outlining a discounted cash flow forecast for SUPN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Supernus Pharmaceuticals Inc ranked in the 69th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. As for the metrics that stood out in our discounted cash flow analysis of Supernus Pharmaceuticals Inc, consider:

  • Supernus Pharmaceuticals Inc's weighted average cost of capital (WACC) is 9%; for context, that number is higher than only 21.78% of tickers in our DCF set.
  • Supernus Pharmaceuticals Inc's effective tax rate, as measured by taxes paid relative to net income, is at 18 -- greater than 73.36% of US stocks with positive free cash flow.
  • Relative to other stocks in its sector (Healthcare), Supernus Pharmaceuticals Inc has a reliance on debt greater than 65.65% of them.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

IIN, STAA, HAE, HCA, and ALXN can be thought of as valuation peers to SUPN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.

SUPN Latest News Stream

Event/Time News Detail
Loading, please wait...

SUPN Latest Social Stream

Loading social stream, please wait...

View Full SUPN Social Stream

Latest SUPN News From Around the Web

Below are the latest news stories about Supernus Pharmaceuticals Inc that investors may wish to consider to help them evaluate SUPN as an investment opportunity.

Supernus Pharmaceuticals Stock Getting Closer To Key Technical Measure

A Relative Strength Rating upgrade for Supernus Pharmaceuticals shows improving technical performance. Will it continue?

Yahoo | June 10, 2021

Supernus to Present at Jefferies Virtual Healthcare Conference

ROCKVILLE, Md., May 25, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will present a company overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021, at 1:30 p.m. ET. A live webcast of the presentation can be accessed by visiting Events & Presentations in the Investor Relations section on the Company's website at An archived replay will be available for 60 days on the Company's website following the conference. About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals is a biopharmaceutical company...

Yahoo | May 25, 2021

Qelbree™ (viloxazine extended-release capsules), a New Non-Controlled Substance, Now Available for the Treatment of ADHD in Pediatric Patients 6-17 Years of Age

Qelbree™ has proven efficacy in ADHD, with improvement in symptoms as early as the first weekROCKVILLE, Md., May 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that its recent U.S. Food and Drug Administration (FDA) approved treatment Qelbree (viloxazine extended-release capsules) for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age, is now available. For more information on access, ways to save and additional patient support services, visit: “The availability of Qelbree™ has helped to create a shift in the way providers c...

Yahoo | May 24, 2021

Supernus Pharmaceuticals Inc (SUPN) Q1 2021 Earnings Call Transcript

Image source: The Motley Fool. Supernus Pharmaceuticals Inc (NASDAQ: SUPN)Q1 2021 Earnings CallMay 5, 2021, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood afternoon and welcome to Supernus Pharmaceuticals First Quarter 2021 Financial Results Conference Call.

Yahoo | May 6, 2021

Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Miss Estimates

Supernus (SUPN) delivered earnings and revenue surprises of -57.69% and -0.63%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 5, 2021

Read More 'SUPN' Stories Here

SUPN Price Returns

1-mo 7.76%
3-mo 30.39%
6-mo 52.38%
1-year 35.75%
3-year -39.33%
5-year 87.09%
YTD 32.51%
2020 6.07%
2019 -28.60%
2018 -16.64%
2017 57.82%
2016 87.87%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9411 seconds.